

This Semi-annual shareholder report contains important information about UltraShort Nasdaq Biotechnology (the “Fund”) for the period of June 1, 2024 to November 30, 2024. You can request additional information about the Fund by contacting us at 866-776-5125. You can also find additional information about the Fund at: [https://www.proshares.com/geared\\_shareholder\\_reports](https://www.proshares.com/geared_shareholder_reports).

### What were the Fund's costs for the period?

(based on a hypothetical \$10,000 investment)

Ticker	Costs of a \$10,000 investment	Costs paid as a percentage of a \$10,000 investment*
BIS	\$45	0.95%
* Annualized		

### Key Fund Statistics

Net Assets	\$3,511,018
Number of Portfolio Holdings	8
Portfolio Turnover Rate	-%

### Market Exposure

Investment Type	% of Net Assets
Swap Agreements	(200)%
<b>Total</b>	<b>(200)%</b>

“Market Exposure” includes the value of total investments (including the contract value of any derivatives) and excludes any short-term investments and cash equivalents.

### Sector Weights

Sector	% of Exposure
Biotechnology	80.7%
Pharmaceuticals	14.5%
Life Sciences Tools & Services	4.1%
Health Care Providers & Services	0.5%
Health Care Equipment & Supplies	0.2%

### Holdings

The UltraShort Nasdaq Biotechnology primarily invests in non-equity securities, which may include: swap agreements, futures contracts, repurchase agreements and U.S. Government securities.

